About Glycerol-3-phosphate dehydrogenase 1-like protein
Glycerol-3-phosphate dehydrogenase 1-like protein (GPD1L) is a protein
from Homo sapiens identified by UniProt accession
Q8N335, 351 residues long.
MolForge cross-references it against 0 known binders and
79 disease associations.
Target properties
| Protein name | Glycerol-3-phosphate dehydrogenase 1-like protein |
|---|
| UniProt accession | Q8N335 |
|---|
| Gene | GPD1L |
|---|
| Organism | Homo sapiens |
|---|
| Length | 351 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (79)
Diseases linked to this target (Open Targets).
- Brugada syndrome · score 0.21
- Abnormality of the cardiovascular system · score 0.19
- Prolonged QT interval · score 0.15
- dilated cardiomyopathy · score 0.12
- schizophrenia · score 0.12
- sudden cardiac arrest · score 0.11
- Wolff-Parkinson-White Syndrome · score 0.11
- attention deficit hyperactivity disorder · score 0.09
- neoplasm · score 0.09
- lung adenocarcinoma · score 0.08
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q8N335-F1 | alphafold | PREDICTED | 96.84 | — |
Amino-acid sequence (351 residues)
MAAAPLKVCI VGSGNWGSAV AKIIGNNVKK LQKFASTVKM WVFEETVNGR KLTDIINNDH ENVKYLPGHK LPENVVAMSN LSEAVQDADL LVFVIPHQFI HRICDEITGR VPKKALGITL IKGIDEGPEG LKLISDIIRE KMGIDISVLM GANIANEVAA EKFCETTIGS KVMENGLLFK ELLQTPNFRI TVVDDADTVE LCGALKNIVA VGAGFCDGLR CGDNTKAAVI RLGLMEMIAF ARIFCKGQVS TATFLESCGV ADLITTCYGG RNRRVAEAFA RTGKTIEELE KEMLNGQKLQ GPQTSAEVYR ILKQKGLLDK FPLFTAVYQI CYESRPVQEM LSCLQSHPEH T
Explore Glycerol-3-phosphate dehydrogenase 1-like protein with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets